Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Robert I. Haddad(Georgetown University), Makoto Tahara(National Cancer Center Hospital East), Clíona Grant(St. James's Hospital), Christine H. Chung(Moffitt Cancer Center), Aaron R. Hansen(Princess Margaret Cancer Centre), Jérôme Fayette(Université Claude Bernard Lyon 1), Michael Schenker(Sorbonne Université), Tariq Aziz Khan(Bristol-Myers Squibb (United States)), Karen Miller-Moslin(Bristol-Myers Squibb (United States)), Sébastien Salas(Assistance Publique Hôpitaux de Marseille), Peter Grell(Masaryk Memorial Cancer Institute), Denis Soulières(Centre Hospitalier de l’Université de Montréal), A. Argiris(Thomas Jefferson University), John Walker(University of Alberta), Mustimbo Roberts(Bristol-Myers Squibb (United States)), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Åse Bratland(Oslo University Hospital), Robert L. Ferris(University of Pittsburgh), Wei Li(Guangdong Pharmaceutical University), Sérgio de Azevedo(Hospital de Clínicas de Porto Alegre), Alexandre Coutté, Caroline Even(Institut Gustave Roussy), Rebecca Redman(University of Louisville)
Cited by 73
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
|Journal of Clinical Oncology|2008|1.6k